Oxbow Advisors LLC Takes Position in Regeneron Pharmaceuticals, Inc. $REGN

Oxbow Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 2nd quarter, Holdings Channel reports. The fund acquired 5,359 shares of the biopharmaceutical company’s stock, valued at approximately $3,342,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. WPG Advisers LLC raised its stake in Regeneron Pharmaceuticals by 312.5% in the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 25 shares in the last quarter. Western Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals during the first quarter valued at approximately $26,000. SHP Wealth Management purchased a new position in Regeneron Pharmaceuticals in the 4th quarter worth approximately $26,000. Titan Wealth CI Ltd purchased a new position in Regeneron Pharmaceuticals in the 4th quarter worth approximately $29,000. Finally, Kemnay Advisory Services Inc. bought a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth $31,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 0.5%

REGN stock opened at $810.24 on Wednesday. The company has a market capitalization of $83.42 billion, a PE ratio of 20.03, a price-to-earnings-growth ratio of 1.37 and a beta of 0.21. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. Regeneron Pharmaceuticals, Inc. has a one year low of $541.00 and a one year high of $821.11. The company’s 50 day moving average price is $683.57 and its two-hundred day moving average price is $714.66.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. During the same quarter in the prior year, the company earned $12.81 EPS. The firm’s revenue was up 16.7% on a year-over-year basis. As a group, analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th will be paid a $0.94 dividend. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is currently 9.29%.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Leerink raises price target: Leerink Partners increased its REGN price target from $641 to $824, implying modest additional upside. However, the firm retained a “market perform” rating, suggesting limited conviction in a stronger near-term advance. Benzinga analyst price target report
• Neutral Sentiment: Class-action deadline approaches: Several law firms, including Pomerantz, Hagens Berman, Faruqi & Faruqi, and The Schall Law Firm, reminded investors of a September 14, 2026 deadline to seek lead-plaintiff status in a securities lawsuit. These announcements largely repeat previously reported information and do not represent a new financial or regulatory finding. Pomerantz investor alert
• Negative Sentiment: Litigation highlights clinical-trial concerns: The lawsuits allege that Regeneron made misleading statements about clinical differentiation and slowing event accrual in the Phase 3 fianlimab-Libtayo study, potentially understating the risk that the trial would miss its primary endpoint. The trial failure reportedly erased roughly $11 billion in market value and could create ongoing legal costs, reputational risk, and uncertainty around the program’s commercial prospects. The allegations have not been proven. Hagens Berman Regeneron class-action notice

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Sanford C. Bernstein upgraded shares of Regeneron Pharmaceuticals to a “hold” rating in a research report on Wednesday, July 29th. Piper Sandler cut their target price on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating for the company in a research report on Thursday, July 9th. Royal Bank Of Canada increased their target price on Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the company a “sector perform” rating in a research note on Friday, July 31st. Wells Fargo & Company raised their price target on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an “equal weight” rating in a research report on Friday, July 31st. Finally, Leerink Partners lifted their price target on Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the stock a “market perform” rating in a research note on Monday. Sixteen investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $801.70.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $320,000.00. Following the transaction, the director owned 603 shares in the company, valued at approximately $482,400. The trade was a 39.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur F. Ryan sold 200 shares of the business’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the completion of the sale, the director directly owned 17,303 shares of the company’s stock, valued at approximately $11,249,545.45. This trade represents a 1.14% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,400 shares of company stock worth $1,090,030 over the last three months. Company insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.